Biotech News

ImmunityBio Announces ANKTIVA® Plus BCG Meets Primary Endpoint in BCG-Naïve Non-Muscle Invasive Bladder Cancer Randomized QUILT-2.005 Trial

ImmunityBio (IBRX)ImmunityBioClinical readout

ANKTIVA ® plus BCG met the primary efficacy endpoint in the randomized registrational trial of 370 subjects comparing intravesical ANKTIVA plus BCG with BCG alone; additional study details will be presented at an upcoming medical congress ANKTIVA plus BCG is the first chemotherapy-free

Related news

IBRXImmunityBio2026-10-21 11:30 EST

ImmunityBio Announces Database Lock for Registrational Trial of Locally Delivered, Chemotherapy-Free ANKTIVA® Plus BCG in BCG-Naïve Non-Muscle Invasive Bladder Cancer

IBRXImmunityBio2026-10-16 15:49 EST

ImmunityBio Reports Phase 3 Data Showing 84% Cystectomy Avoidance at Three Years and Complete Responses Beyond 53 Months with ANKTIVA® Plus BCG in BCG-Unresponsive NMIBC With CIS, With or Without Papillary Tumors

URGNUroGen Pharma2026-11-02 13:00 EST

UroGen Announces First Patient Dosed in Phase 1 Trial of UGN-501, an Investigational Next-Generation Oncolytic Virus for Non-Muscle Invasive Bladder Cancer

RVMDRevolution Medicines2026-10-20 12:00 EST

Revolution Medicines Begins Treating Patients in Phase 3 RASolve 308 Trial Evaluating Zoldonrasib in Combination with Pembrolizumab and Chemotherapy as First-Line Treatment for Patients with Metastatic RAS G12D Non-Squamous Non-Small Cell Lung Cancer

RVMDRevolution Medicines2026-11-19 23:05 EST

Revolution Medicines Presents Updated Phase 1/2 Data for RASONQUE® (daraxonrasib) Plus Chemotherapy in First-Line Metastatic Pancreatic Cancer at ENA 2026

BNTXBioNTech2026-10-26 09:00 EST

BioNTech and DualityBio Announce Topline Results of the DYNASTY-Breast02 Global Phase 3 Clinical Trial Evaluating Trastuzumab Pamirtecan in HR+/HER2-low Metastatic Breast Cancer

BMYBMYBristol-Myers Squibb Company2026-10-26 07:30 EST

Izalontamab Brengitecan (Iza-Bren) Doubles Median Progression-Free Survival in Patients with Previously-Treated EGFR-Mutated Non-Small Cell Lung Cancer Compared to Chemotherapy in the Phase 3 PANKU-Lung01 Study

JNJJohnson & Johnson2026-10-25 14:24 EST

Subcutaneous RYBREVANT®▼ (amivantamab) demonstrates 77% overall response rate in first-line treatment of patients with certain types of advanced head and neck cancer

BMYBMYBristol-Myers Squibb Company2026-10-25 07:30 EST

BioNTech and Bristol Myers Squibb Report Encouraging Global Phase 2 data for Pumitamig in Advanced NSCLC After Progression on Immunotherapy Plus Chemotherapy

REGNRegeneron Pharmaceuticals2026-10-12 16:06 EST

Pasatru™ (garetosmab-grts) Demonstrates Zero New Heterotopic Ossification (HO) Lesions in Adult Fibrodysplasia Ossificans Progressiva (FOP) Patients During OPTIMA Trial Extension

ImmunityBio

Immune-Based Cancer Therapies ImmunityBio develops therapies that activate innate and adaptive immune responses against cancer. Its platform combines cytokine biology, cell therapy and immunotherapy combinations. ANKTIVA ANKTIVA is an IL-15 superagonist approved with BCG for selected patients with BCG-unresponsive non-muscle-invasive...

Recent company news

Stock data

Close
6.57 USD
Market cap
7.57B USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States